What is Vydura and what it is used for?
Vydura contains the active ingredient rimegepant, that stops the activity of a substance in the body called calcitonin gene-related peptide (CGRP). People with migraine may have increased levels of CGRP. Rimegepant attaches to the receptor for CGRP, reducing the ability of CGRP to also attach to the receptor. This reduces the activity of CGRP and has two effects:

1. it can stop an active migraine attack, and
2. it can decrease the number of migraine attacks that occur when taken preventively.

Vydura is used to treat and prevent migraine attacks in adults.

The medicine can only be obtained with a prescription.


Reference Information
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Vydura visit the electronic Medicines Compendium (eMC).

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.